AMNEAL PHARMACEUTICALS, INC. (AMRX) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 5.96M USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 2.56B USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 3.78B USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $5.96M | $2.56B | (m) | (m) | $3.78B | (m) |
| 2026-03-31 | (m) | (m) | $6.20M | $2.57B | (m) | (m) | $3.54B | (m) |
| 2025-12-31 | (m) | (m) | $6.76M | $2.57B | (m) | (m) | $3.68B | (m) |
| 2025-09-30 | (m) | (m) | $7.20M | $2.57B | (m) | (m) | $3.60B | (m) |
| 2025-06-30 | (m) | (m) | $31.18M | $2.15B | (m) | (m) | $3.42B | (m) |
| 2025-03-31 | (m) | (m) | $31.79M | $2.15B | (m) | (m) | $3.37B | (m) |
| 2024-12-31 | (m) | (m) | $224.21M | $2.16B | (m) | (m) | $3.50B | (m) |
| 2024-09-30 | (m) | (m) | $224.69M | $2.17B | (m) | (m) | $3.46B | (m) |
| 2024-06-30 | (m) | (m) | $225.16M | $2.18B | (m) | (m) | $3.51B | (m) |
| 2024-03-31 | (m) | (m) | $33.66M | $2.38B | (m) | (m) | $3.46B | (m) |
| 2023-12-31 | (m) | (m) | $34.13M | $2.39B | (m) | (m) | $3.47B | (m) |
| 2023-09-30 | (m) | (m) | $30.53M | $2.54B | (m) | (m) | $3.69B | (m) |
| 2023-06-30 | (m) | (m) | $30.41M | $2.55B | (m) | (m) | $3.70B | (m) |
| 2023-03-31 | (m) | (m) | $29.96M | $2.56B | (m) | (m) | $3.63B | (m) |
| 2022-12-31 | (m) | (m) | $29.96M | $2.59B | (m) | (m) | $3.80B | (m) |
| 2022-09-30 | (m) | (m) | $29.94M | $2.61B | (m) | (m) | $3.87B | (m) |
| 2022-06-30 | (m) | (m) | $29.92M | $2.62B | (m) | (m) | $4.04B | (m) |
| 2022-03-31 | (m) | (m) | $30.52M | $2.67B | (m) | (m) | $3.89B | (m) |
| 2021-12-31 | (m) | (m) | $30.61M | $2.68B | (m) | (m) | $3.94B | (m) |
| 2021-09-30 | (m) | (m) | $30.47M | $2.69B | (m) | (m) | $3.97B | (m) |
| 2021-06-30 | (m) | (m) | $30.46M | $2.72B | (m) | (m) | $4.02B | (m) |
| 2021-03-31 | (m) | (m) | $29.82M | $2.73B | (m) | (m) | $3.96B | (m) |
| 2020-12-31 | (m) | (m) | $44.23M | $2.74B | (m) | (m) | $4.01B | (m) |
| 2020-09-30 | (m) | (m) | $29.78M | $2.76B | (m) | (m) | $4.04B | (m) |
| 2020-06-30 | (m) | (m) | $29.76M | $2.76B | (m) | (m) | $4.06B | (m) |
| 2020-03-31 | (m) | (m) | $29.74M | $2.77B | (m) | (m) | $4.39B | (m) |
| 2019-12-31 | (m) | (m) | $21.48M | $2.61B | (m) | (m) | $3.67B | (m) |
| 2019-09-30 | (m) | (m) | (m) | $2.61B | (m) | (m) | $3.70B | (m) |
| 2019-06-30 | (m) | (m) | (m) | $2.62B | (m) | (m) | $4.26B | (m) |
| 2019-03-31 | (m) | (m) | (m) | $2.63B | (m) | (m) | $4.38B | (m) |
| 2018-12-31 | (m) | (m) | $21.45M | $2.63B | (m) | (m) | $4.35B | (m) |
| 2018-06-30 | (m) | (m) | (m) | $2.64B | (m) | (m) | $4.54B | (m) |
| 2017-12-31 | (m) | (m) | (m) | $1.36B | (m) | (m) | $1.34B | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |